Trial Profile
A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Sponsors Stealth BioTherapeutics
- 22 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.